Clinical Oncology Next Generation Sequencing Expands Potential in Genomic Characterization

Next generation sequencing (NSG) technologies in clinical oncology have considerably expanded the avenue in genetic analysis of tumors, opening new landscapes in cancer treatment. The drive for next generation sequencing in a range of applications stemmed from the need for high throughput and cost-effective approach for genomic characterization of cancer. In applications pertaining to identifying cancer-related variants, clinical oncology next generation sequencing has imparted benefits of unprecedented speed and low cost. Companies around the world relentlessly engaged in expanding the armamentarium of their prognostic and predictive biomarkers for several cancer syndromes see vast avenues in NSG.

Get Sample Copy of this Report @

Search for Novel Diagnostic, Prognostic, and Therapeutic Targets Open New Horizons

The prospects in the market are vast. With continuous advances in molecular analysis solid tumor classification methods, new applications of NSG have entered from the research to the clinical realm. This is a key factor helping in the evolution of the clinical oncology NSG market. A prominent application that is gathering traction for market players is analysis of whole-genome sequence and whole-exome sequence of tumors. The applications in RNA sequencing of cancer and targeted genome profiling are also showing considerable market potential.

Companies in the pursuit of finding novel diagnostic, prognostic, and therapeutic targets for multiple cancer types are adopting new sequencing technologies to catalogue mutations. NSG has enabled them to study gene expression alterations in scores of tumors of different subtypes, with remarkable speed and less cost than earlier sequencing technologies.

Clinicians Focused on Improving Chemotherapy Outcomes to Harness Potential of NSG      

Over the past decade, NSGs saw a remarkable role in understanding of molecular basis of tumor progression and treatment response. Efforts of clinicians in improving results of chemotherapy or targeted therapy, have turned their attention toward genetic diagnostic screening methods. Recent cases in point are hereditary breast and ovarian cancer, those characterized by high-lifetime risk.

Check Table of Contents of this Report @

Growing focus of healthcare industry in expanding transcriptomic landscapes of cancer has also been fueling the expansion of the clinical oncology NSG market. This includes expanding research funding in molecular cell biology of cancers. In the coming years, this will gain momentum from the copious demands for molecularly targeted therapies in clinical oncology.